Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.

ABSTRACT: Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with multiple myeloma (MM). The International Myeloma Working Group (IMWG) developed guidelines recommending primary thromboprophylaxis, in those identified at high-risk of VTE by the presence of risk factors. The National Comprehensive Cancer Network (NCCN) has adopted these guidelines; however, they lack validation. We sought to develop and validate a risk prediction score for VTE in MM and to evaluate the performance of the current IMWG/NCCN guidelines. Using 4446 patients within the Veterans Administration Central Cancer Registry, we used time-to-event analyses to develop a risk score for VTE in patients with newly diagnosed MM starting chemotherapy. We externally validated the score using the Surv

SUBMITTER: Sanfilippo KM 

PROVIDER: S-EPMC7058359 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature